Skip to main content
. 2016 Oct 13;7(47):77306–77318. doi: 10.18632/oncotarget.12639

Figure 7. Cooperation between DcR3 and TGF-β3/SMAD-EMT signaling-related protein expression correlated with survival and survival times in CRC patients.

Figure 7

A-J. Kaplan-Meier analysis of the relationship ofconcurrent N-cadherin and E-cadherin expression (A, P<0.001), DcR3 and N-cadherin expression (B, P=0.003), DcR3 and E-cadherin expression (C, P=0.046), DcR3 and TGF-β3 (D, P=0.028), DcR3 and smad2 expression (E, P=0.028), DcR3 and smad3 expression (F, P=0.033), TGF-β3 and smad2 expression (G, P=0.006), TGF-β3 and smad3 expression (H, P=0.008), DcR3/N-cadherin and E-cadherinexpression (I, P=0.023), and DcR3/TGF-β3 and smad2expression (J, P=0.008) with recurrence and overall survival in CRC patients. Activation of the TGF-β3/SMAD pathway was associated with shorter overall survival times. Patients expressing DcR3 and exhibiting TGF-β3/SMAD pathway activity had poorer prognoses. (K) Summary diagram showing cooperation between DcR3 and TGF-β3/SMAD-EMT signaling-related protein expression in CRC.